Medicon Valley Cluster

A Danish-Swedish Life Science Cluster

Medicon ValleyA Danish-Swedish Life Science Cluster Located in the Øresund Region

© Medicon Valley Alliance 2007Photos: Brigdephoto, Copenhagen Capacity, Medicon Valley Alliance, NeuroSearch and VisitDenmark

Contents04 Prologue

06 Chapter 1 | Welcome to Medicon Valley • Get more information

09 Chapter 2 | Business Environment • Strongholds • A growing industry • International attention • A mature pipeline • Continuous growth and success • Business is easy • Lean business • Productive work culture

14 Chapter 3 | Science Base • Funding • International ranking • Centres of Excellence • Medicines research academy

18 Chapter 4 | Access to Talent • Reseachers and life science specialists • Management expertise • High mobility • Language skills • Academic resources • The Øresund University

23 Chapter 5 | Access to Capital • Local investors • International investors present in Medicon Valley • International exposure of local companies • Looking ahead

26 Chapter 6 | Support Structure • Tech transfer organisations and incubators • Full service science • A comprehensive population registration system • An exceptional place to develop personalised medicine • Registration and certifi cation of medicine and medical devices • Contract research and manufacturing organisations of a high standard

32 Chapter 7 | Infrastructure • Medicon Valley – a new Scandinavian base

34 Chapter 8 | Quality of Life • Advanced lifestyle • A perfect balance • Vibrant culture • Close to nature

39 Chapter 9 | Point of Entries • Medicon Valley Alliance • Copenhagen Capacity • Region Skåne

”Add to that a comprehensive social services network, a safe society where everyone

speaks English and carefully planned cities with easy commuting, and the Scandinavian

biotech industry appears to offer an unbeatable combination.”

NewScientist, 5 May 2007

Medicon Valley is a bi-national cluster that spans

the island of Zeeland in eastern Denmark and

the Skåne region of southern Sweden.

Medicon Valley is one of Europe’s strongest life

science clusters with a large number of life

science companies located within a very small

geographical area. Local and international in-

vestors have provided the capital needed for

the continued growth of these companies. To-

gether with specialised service providers such

as different CROs, CMOs, consultants and patent

attorneys, all the competences required to bring

new and innovative products to the market are

available.

In Medicon Valley you will fi nd a unique interplay

between businesses, hospitals, universities and

public research institutions – a successful prac-

tise of the triple helix model. Based on this model,

interaction and network activities take place

among the various public and private life science

players. This interaction results in a dynamic en-

vironment rich in innovation and knowledge sha-

ring – prerequisites for new company formation

and growth of the cluster.

Welcome to Medicon Valley

These unique conditions have led Medicon Valley

to foster one of the most impressive pipelines

within commercially attractive therapeutic areas,

such as diabetes, neuroscience, infl ammation, in-

fectious diseases and cancer.

There are many good reasons why the world is

taking a close look at Medicon Valley.

GET MORE INFORMATION

To investigate the opportunities in Medicon

Valley further, feel free to contact the point of

entries listed below. Contact information is pla-

ced at the back of the brochure.

• The cluster organisation Medicon Valley

Alliance – if you wish to attain information

about life science in Medicon Valley and

contact information on the public and pri-

vate players.

• The investment promotion agencies Copen-

hagen Capacity (Denmark) and Region Skåne

(Sweden) – if you are interested in knowing

more about business opportunities or are

looking to invest in Medicon Valley.

Page 6 | Chapter 1 | Welcome to Medicon Valley

The Medicon Valley Ambassador Programme

No cluster can sustain growth in isolation. Life science technologies, investment opportunities

and research collaborations are all global in their perspectives and the future belongs to clus-

ters that can enter into productive win-win relations with other growing regions. That is why

Medicon Valley Alliance has recently developed a strategic globalisation initiative, called the

Medicon Valley Ambassador Programme. This initiative involves the establishment of close

strategic ties between important life science clusters around the globe with exchanges of

life science ambassadors. The ambassadors will work together to develop win-win opportuni-

ties between clusters by scouting for science and business opportunities and by enhancing

networking between the participating clusters. Get more information at www.mva.org.

The Region

Medicon Valley lies in the Danish-Swedish Øresund Region, which consists of Zeeland and Skåne and

covers a total of 21,000 km². It is the new regional centre of northern Europe with the Danish

capital Copenhagen as the pivotal point.

The Øresund Region has a large number of advantages:

• The largest metropolitan area in Scandinavia

• Great access to the Scandinavian, North European and Baltic markets

• Regional proximity and short distances

• Well-developed infrastructure

• Very good language skills

• Excellent quality of life

Cluster Facts

• Population of approx. 3.5 million

• Companies with R&D and/or production: Approx. 100 (red) biotech companies, 25 pharma

companies (7 major) and 100 medtech companies

• International companies with affiliates in Medicon Valley: More than 200 pharma companies

and 170 medtech companies

• Approx. 40,000 employees in the private life science sector

• Approx. 10,000 life science researchers in the private and public life science sector

• 12 universities, 5 of which supply life science related educations

• Approx. 150,000 students, 45,000 of whom study life science

• Approx. 2,600 life science PhD students are enrolled at the universities of Copenhagen and Lund

• Approx. 7,000 life science university students graduate every year

• 32 hospitals, 11 of which are university hospitals

• 6 science parks with a significant focus on life science

• 6 incubators, 2 of which have a significant focus on life science

• More than 50 contract research organisations and contract manufacturing organisations

Page 7 | Chapter 1 | Welcome to Medicon Valley

The Vision for Medicon Valley

Medicon Valley will be among the fi ve most

attractive bioregions worldwide, recognised

for:

• An excellent scientifi c environment and

pool of talent

• Outstanding access to knowledge sha-

ring and technology transfer between

universities, hospitals and industry

• An innovative and entrepreneurial environ-

ment, with competitive enterprises

• A truly international perspective and glo-

bal network

STRONGHOLDS

The major pharmaceutical corporations found in

Medicon Valley – Novo Nordisk, AstraZeneca, LEO

Pharma, H. Lundbeck, Nycomed, Ferring Pharma-

ceuticals and ALK-Abelló – constitute the back-

bone in what has become Europe’s most densely

packed life science cluster. Based on a long

research commitment, the cluster holds core

competences in therapeutic areas like diabetes/

metabolism, neuroscience, cancer, infl ammation

and allergy. Furthermore, Medicon Valley is in the

forefront of personalised medicine.

A GROWING INDUSTRY

Biotech is one of the fastest growing industries

within life sciences. The majority of the region’s

more than a hundred biotech companies has

emerged since the mid-1990s. Many new com-

panies have managed to bring their research

forward into the clinical stages of development.

The sustained growth and maturing of these

companies is being secured by a constant injec-

tion of mostly international venture capital to

the region. In 2006, this amounted to more than

EUR 700 million and ensured Denmark ranked as

the number one nation in Europe as measured

by the amount of private capital invested as a

percentage of gross domestic product (Nature

Biotechnology, Dec. 2006).

INTERNATIONAL ATTENTION

Biotech companies in Medicon Valley have suc-

ceeded in making an impact on the international

scene. In December 2006, Genmab and Glaxo-

SmithKline closed the largest ever global biotech

licence agreement with a potential value of EUR

1.5 billion. In January 2007, BioInvent entered a

EUR 135 million co-development agreement with

Genentech to develop and commercialise Bio-

Invent’s proprietary antibody candidate drug for

the US market. In spring 2007, Bavarian Nordic

closed a EUR 1.2 billion deal to deliver smallpox

vaccines to the US Department of Health and

Human Services. In addition, Active Biotech has

signed several agreements with international

partners within the areas of autoimmune disea-

ses and transplant rejection.

Business Environment

Medicon Valley is characterised by a healthy busi-

ness environment with extensive collaboration

between life science companies, academic resear-

chers and clinicians. It is very easy to establish

new companies in the region and a tangible result

has been the occurrence of a signifi cant number

of new and growing life science companies both

within red biotech and medical technology. This

development has led to a substantial growth in

the number of employees and put together the

life science industry in Denmark and Sweden now

ranks second in the world, behind the US (Nature

Biotechnology, Jan. 2007).

”The level of innovation in Medicon Valley is high, which in combination with

a fl ourishing VC market and simple regulations, makes the conditions unique for business development.”

Bo-Ragnar TolfManaging Director

ACADIA Pharmaceuticals(Malmö, Sweden)

Page 9 | Chapter 2 | Business Environment

A MATURE PIPELINE

From the modest beginnings a decade or so ago,

Medicon Valley has advanced into an establis-

hed life science cluster consisting of companies

with a wide range of candidates in their re-

spective pipelines.

More biotech companies than ever have pro-

jects in clinical trials and in total, products tar-

geted towards almost 200 different indications

are present in the different phases of clinical

development. Leaving out big pharma companies,

close to 150 new indications are under clinical

investigation by the smaller biotech companies.

Around 70% of all clinical indications under inve-

stigation fall within the four therapeutic areas

where Medicon Valley has secured its internatio-

nal reputation. While the big pharma companies

”If you want access to fi rst-class research conditions,

come to Medicon Valley.” Bertil Lindmark

Global Vice PresidentAstraZeneca (Lund, Sweden)

are predominantly involved in research within

their traditional therapeutic areas, biotech com-

panies play a role in all therapeutic areas, but

have their most signifi cant contribution within

cancer research and immunology.

The strength and research intensity of the Medi-

con Valley cluster is illustrated by the region’s

drug development pipeline which is comparable

both quantitatively and qualitatively with the

output produced by geographically larger areas

in Europe.

Total pipeline 2006Therapeutic indications Incl. big pharma


Pipeline 2006Therapeutic indications Only biotech

CONTINUOUS GROWTH AND SUCCESS

The positive development in Medicon Valley is

expected to continue in the years to come. The

optimism in the region is apparent from the fact

that more than ten biotech companies expect

to go public in 2008-2010. The extensive pipe-

line of new products will continue to develop and

eventually lead to the launch and marketing of

many new and better therapeutic agents. More

companies will generate revenue and more com-

panies will be founded by a new generation of

entrepreneurs thanks to the availability of risk

willing capital.

Another positive sign that indicates a conti-

nuous growth is the expansion and building of

new science parks and incubators in Medicon

Valley. During 2007 the Lund Bioincubator ope-

ned, and in less than 2 years another science

park with incubator, COBIS, is to be opened clo-

se to Copenhagen Biocenter.

BUSINESS IS EASY

Medicon Valley constitutes a business friendly

region, and in particular for R&D intensive com-

panies. Corporate taxation rates are among the

lowest in Europe and effi cient and digitalised

government procedures means that companies

are able to reduce their administrative costs

and allocate resources to core activities.

Setting up and operating a business in Medicon

Valley is surprisingly easy. The public sector

boasts world-class quality while managing to

operate both quickly and effi ciently. The level

of regulation imposed on start-ups in Denmark

and Sweden is minimal, and this means the area

offers some of the easiest, fastest and chea-

pest start-up procedures to be found anywhere

– as reported by the World Bank.

A survey from the internationally acknowledged

Institute for Management Development (IMD)

shows that Danish and Swedish bureaucracy is

very low, and bribery and corruption is virtually

non-existent. Furthermore, the legal environment

is such that it does not restrain R&D activities.

In Medicon Valley, public authorities work with

companies, not against them.

LEAN BUSINESS

Lean is a way of life in Medicon Valley that busi-

nesses benefi t from. In few other places is it

so easy to interact with government services.

Regulation is kept to a minimum and is based on

trust and self-regulation rather than strict re-

gulatory controls. The quality of public services

is at its highest level and means corporations

are relieved of social security burdens.

The labour market in Sweden and Denmark is to a

large extent built on the collective agreements

between unions and employers. It is relatively

simple to employ and give notice to employees

in Sweden and Denmark – certainly compared

with much of Europe. The fl exicurity model with

liberal hiring-and-fi ring rules, combined with a

high level of social security plays an important

role, especially in Denmark. It enables companies

to quickly adapt to market changes.

PRODUCTIVE WORK CULTURE

The working environment in Medicon Valley is

attractive to companies seeking employees who

can take responsibility and work in teams that

transcend traditional functions. The work cul-

ture is a rare mix of lean, effi cient work styles

galvanised by a constant strive for new ideas

to improve business processes. Many foreign

companies have found that this work culture

facilitates higher productivity levels and better

results. The work culture leaves room for infl u-

ence and responsibility. As a result, employees

stand out as the most satisfi ed and motivated

in international rankings.

”The proximity and mobility of high quality labour in the region allows us to stay innovative.”Kurt Erling BirkPresident and Chief Executive Offi cerAmbu (Ballerup, Denmark)


”It is a pleasure working with the creative Scandinavians who seem to be reinventing not just biotech, but the very way business is done. I see

this as the makings of a competitive hub for innovative companies, entrepreneurs and technologies in the very near future.”

Ishan GuptaHead of Sales & Marketing

ViroGates (Lyngby, Denmark)

��

��

��

��

��

��

��

��

��

��

Science Base

”The science base here is excellent and this goes for several therapeutic fi elds.

Within diabetes in particular, Medicon Valley is undoubtedly a global hotspot.”

Mads Krogsgaard ThomsenExecutive Vice President and Chief Science Offi cer

Novo Nordisk (Bagsværd, Denmark)

Page 14 | Chapter 3 | Science Base

The two largest universities in Scandinavia are

Lund University (LU) and the University of Copen-

hagen (UC) in Medicon Valley. Together with the

other universities that have life science edu-

cations (Danish Technical University (DTU) and the

universities in Malmö and Roskilde), they house

45,000 life science students.

FUNDING

In Medicon Valley, both private and public R&D

spending is ample. Health-related biotechnology

and life sciences are strategic focus areas in

Denmark and Sweden. Primary funding comes

from the Danish Ministry for Science, Technology

and Development, the Swedish Research Council,

the Swedish Strategic Research Foundation

and the Swedish Governmental Agency for Inno-

vation Systems (VINNOVA).

Although Sweden is already spending more than

3% of GDP on research (3.7% compared to 2.6%

in Denmark), public research spending is below 1%

in both countries. Both governments are dedi-

cated to increase their part.

Private foundations provide signifi cant contri-

butions to public research. The Knut and Alice

Wallenberg Foundation (KAW Foundation) is the

most important private contributor to infra-

structure in Sweden, whereas the Novo and

Lundbeck foundations play an equally important

role in Denmark.

INTERNATIONAL RANKING

The University of Copenhagen and Lund Univer-

sity are both ranked among the hundred best

universities in the world of 500 ranked univer-

sities. In fact, the University of Copenhagen is

ranked the best in Scandinavia and number 8 in

Europe (Shanghai Jiao Tong, 2007).

A recent bibliometric study ranked Denmark and

Sweden as numbers 3 and 5 respectively, after

the US and Switzerland at the top (Veten-

skapsrådets rapportserie 13: 2006). About half

of all publications from the region are within

medicine and 25% within related sciences (The

Øresund Science Region: a cross-border part-

nership between Denmark and Sweden, OECD,

2006).

RESEARCH INFRASTRUCTURE

Medicon Valley universities are supporting re-

search of the very highest international stan-

dard and the focus on biotechnology and medi-

cine has created several brand new research

centres.

One such is BMC, the Biomedical Center at LU.

This has been gradually enlarged to host 110

research groups with 800 scientists, working

within immunology, tumour immunology, con-

nective tissue research, molecular signalling,

molecular biology, developmental biology, and

neuroscience and cell biology. The latest addi-

tion from 2006 includes Lund Bio-Incubator with

about ten start-up companies.

CRC, the Clinical Research Centre in Malmö,

houses 400 researchers specifi cally engaged

in diabetes, blood & defence, and public health

research.

Copenhagen Biocenter contains state-of-the-art

laboratories, including animal research facilities

for cancer research, bioinformatics, proteo-

mics and crystallography. The Biocenter houses

among others the BRIC (Biotech Research and

Innovation Centre) research groups. A bio-incu-

bator, COBIS, is being constructed close to the

biocenter and will open in 2009.

The Swedish national research unit MAX-lab in

Lund is due for a major upgrading to MAX 4. It is a

synchrotron radiation laboratory, where e.g. cell

consitutents and biomolecules are studied.

”For academic research, the pos-sibilities for innovative partners in

this region are outstanding.”Bo Ahrén

Head of Medical FacultyLund University (Lund, Sweden)


MEDICINES RESEARCH ACADEMY

The Medicines Research Academy in Copenhagen

will encompass all pharmaceutical disciplines from

early discovery to clinical development, and manu-

facturing. This institution is in a partnership with

industry and the regulatory authorities and also

has links to the research school for Medicines

Development at LU.

Details on public and private research are pre-

sented below in fact boxes for the following fi ve

Areas of Excellence:

• Neuroscience

• Cancer

• Infl ammation, Allergy and Autoimmune Diseases

• Diabetes and Metabolic Diseases

• Infectious Diseases

ESS, the European Spallation Source, might be

hosted in Lund close to MAX-lab from 2017 to

allow advanced neutron scattering research on

the properties of materials and molecules. When

implemented, another 5,000-6,000 researchers

are expected to work in the region.

CENTRES OF EXCELLENCE

Medicon Valley holds a number of Centres of Ex-

cellence. These include centres for nanotechno-

logy and stem cell biology (LU), for bioinformatics

and microbial biotechnology (DTU), for compara-

tive genomics, and epigenetics (UC). The sizes

of the universities make it possible to promote

interdisciplinary research such as neuroscience,

functional food (LU) and drug discovery (UC).

Neuroscience

Public NeuroLund is a program to explore mechanisms of neurodegeneration in cell and animal

models of Parkinson’s, Huntington’s and Alzheimer’s diseases, stroke, epilepsy, depression and

bipolar disorder. NeuroFortis at the Wallenberg Neuroscience Center is a joint effort between

four strong research teams in the fi eld of brain damage and repair, and a pioneering research

group on human embryonic stem cells. UC supports a neuro cluster of nearly 50 senior scientists,

to promote faculty-spanning research projects. It has focus on neuro-degeneration, neuronal

signalling, biological psychiatry, motor control & rehabilitation, imaging and genomics/proteomics.

Private Lundbeck continues developing new anti-depressive drugs and treatments for schizophrenia,

Alzheimer’s and Parkinson’s disease. A number of biotech companies work on proprietary technology

platforms. Examples include Neurosearch (ion channels and transporters), Acadia (G-protein coupled

receptors), Enkam (neuronal cell adhesion molecules), NS Gene (encapsulated cell bio-delivery), Phar-

mexa (immunotherapy), Neuropharma (brain protective substances), Exini Diagnostics, Schizo-

Detect (diagnostic decision support) and QuickCool (rapid brain cooling devices).


Cancer

Public More than ten research groups at BRIC are con-

centrating on oncology and cancer, with the aim to

understand the molecular mechanisms behind the

disease(s). The Danish Cancer Society funds frontline

research in oncology. Create Health is a Centre of

Excellence for translational clinical cancer research

in Lund. The eight research groups, working from

patient samples via preclinical research and tech-

nology development and back to the clinic, aim at fi nding

and applying biomarkers to the diagnoses and treatment

of the individual patient.

Private Several biotech companies are utilizing their

proprietary technology platforms for developing new

cancer treatments. Examples include BioInvent, Gen-

mab, Pharmexa, Symphogen (antibodies), Santaris Phar-

ma (RNA analogues), Nordic Vaccine, Meabco (metal

ions, small molecules developed against new targets),

Active Biotech, Topotarget (small molecules against

new targets) , SpectraCure (photodynamic dosing),

Dako (diagnostics), DanDrit (dendritic cells) and Zgene

(gene diagnostics).

Infl ammation, Allergy and Autoimmune Diseases

Public CCI, Copenhagen Cluster of Immunology with near-

ly 50 senior scientists, focuses on how immune respon-

ses are induced, selected and regulated. The cluster

is linked to the Graduate School of Immunology. IIR,

Institute for Infl ammation Research in Copenhagen,

performs investigations of immunogenicity and aller-

genicity of polypeptides, and monitor (auto) antibody

development in patients receiving biologics. Chip (Chro-

nic infl ammation program), TIM (tissues in motion) and

Blood and defence are major collaborative projects at

Lund University for research on basic mechanisms in

clinical disease, where key components are shared bet-

ween disease such as rheumatoid arthritis, systemic

lupus erythematosus, allergy and MS (multiple sclerosis).

Private AstraZeneca’s research unit focuses on res-

piratory diseases as well as infl ammatory diseases such

as rheumatoid arthritis and osteoarthritis. Other phar-

maceutical and biotech companies develop treatments

for various diseases, e.g. AstraZeneca, Resistentia

(respiratory tract infl ammations), Genmab, Ferring,

Cartela (arthritis) , Active Biotech (MS) , BioInvent

(atherosclerosis), Resistentia (respiratory diseases),

Astion Pharma, Valderm (psoriasis) , AnaMar, Euro-

Diagnostica (diagnostics), Hansa Medical (transplant

rejection), Alsensa, Atonomics, Curalogic, Refl ab and

Chemotechnique Diagnostics (allergy). ALK-Abelló re-

cently launched the fi rst oral vaccine against grass

pollen.

Diabetes and Metabolic Diseases

Public LUDC, Lund University Diabetes Center, performs

research from the fundamental cell biology of insulin-

producing and insulin-responsive cells to the everyday

clinical problems of metabolic control and late-com-

plications. The Antidiabetic Food Centre in Lund is an

inter-disciplinary collaboration between 40 research lea-

ders with the aim to fi nd a basis for the design of func-

tional foods, i.e. food which lowers the risk factors for

obesity, type 2-diabetes and cardiovascular diseases.

UC has several research groups engaged in basic and

applied research within all aspects of both type 1 and

type 2-diabetes.

Private The presence of Novo Nordisk makes Medicon

Valley’s diabetes research broad and deep, covering the

entire fi eld from molecular research to epidemiology.

Steno Diabetes Center is a diabetes research hospi-

tal and international teaching centre, owned by Novo

Nordisk and private-publicly fi nanced by Novo Nordisk

and the Capital Region of Copenhagen. The Hagedorn

Research Institute is an independent basic research

component of Novo Nordisk. It focuses on curing dia-

betes by preserving or reconstituting functional beta-

cell mass. Several Medicon Valley biotech companies are

developing treatments based on proprietary technology

platforms — these include Zealand Pharma (peptides for

T2D), 7TM Pharma (G-protein coupled receptors) and

Rheoscience (in vivo models). ØDA, Øresund Diabetes

Academy, is a cross-regional and cross-sectoral interest

group managed by Medicon Valley Alliance. ØDA fi nances

several PhD scholarships and an annual Diabetes Day.

Infectious Diseases

Public SSI, Statens Serum Institut, controls the diagno-

sis and treatment of infectious diseases and biological

threats. It has a long standing commitment to research

and works with infectious agents, resistant bacteria

and different vaccines. Copenhagen’s CISU, Interna-

tional Health, performs research on drug resistance

and drug development for malaria, tuberculosis and

HIV/AIDS. Immunological Bioinformatics at DTU Cen-

ter for Biological Sequence Analysis has a simulation

model of the human immune system and a database

with all human pathogens, to identify epitopes aiding

the search for new vaccines and therapies. LU has inter-

nationally recognised research groups working with

mechanisms behind bacterial infections. Malmö Uni-

versity Hospital is a WHO global reference laboratory

for diagnostics of Papilloma virus.

Private Several biotech companies work with diagno-

sing, preventing or treating infectious diseases, e.g.

Bavarian Nordic, Pharmexa, Glycom (vaccines), Maxygen,

NatImmune (protein-based therapeutics), Symphogen

(antibodies), Dermagen, LICA Pharmaceuticals, Neobio-

tics (novel anti-microbial peptides and small molecu-

les), and Virogates (diagnostics).

Life science is a very exciting industry, since it

calls for a wide specialisation of the workforce

Many different disciplines are required to bring

new ideas through the different stages, from

discovery through preclinical and clinical develop-

ment, to manufacturing and marketing. New and

emerging technologies offer great opportunities

to challenge unmet medical needs, but the imple-

mentation must be balanced against changing

and often mounting regulatory requirements and

constraints. The complexity is increased even

further by the existence of many different the-

rapeutic areas, adding specifi c requirements for

effi cacy documentation.

One of the highlighted advantages of a life science

region like Medicon Valley is that the clustering

of universities, hospitals, large international and

R&D based pharma and medtech companies, and

hundreds of small and medium enterprises (SMEs),

facilitates technology transfer and access to a

signifi cant pool of talent.

RESEARCHERS AND LIFE

SCIENCE SPECIALISTS

Medicon Valley combines quality and quantity of

life sciences. The number of bio/medical publica-

tions is very high, on average 3,200 per year and

includes a large number of clinical articles, indi-

cating a vivid development of new medicines in

the region. The total is considerably higher for

example, than from the universities of Oxford

(England) or Stanford (US), and slightly higher

than from Karolinska Institutet (Sweden) (Grant

Lewison, 2004).

About 40,000 people are employed in the pri-

vate life science sector in Medicon Valley. The

region houses the global headquarters of the

fi ve international pharma and medtech compa-

nies, Novo Nordisk, H. Lundbeck, Leo Pharma,

Coloplast and Ambu. There is also a signifi cant

R&D site for AstraZeneca and major research

or production units for Ferring Pharmaceuticals,

Nycomed, McNeal, and Gambro. Together these

large companies have more than 6,000 scientists

employed. All the vital competencies needed to

attract qualifi ed life science talent can be found

among the remaining 200 biotechnology and

medical device companies conducting R&D in

Medicon Valley. Vital competencies are also pro-

vided by the more than 50 different service

providers in preclinical or clinical development,

IPRs, regulatory affairs and contract manufac-

turing fi rms. The excellent clinical development

profi le and facilities have attracted an increasing

number of international companies and activities

to the region.

MANAGEMENT EXPERTISE

Over the last decade more than a hundred new

biotech companies have been founded in Medicon

Valley. They have matured and a signifi cant propor-

tion of these are now in late clinical development

stage and close to market approval for their

fi rst products. Many companies have already left

the venture capital phase and are now listed on

the Nordic OMX stock exchange or other smaller

listings. These experiences mean that many exe-

cutives have hands-on know-how about all critical

facets of entrepreneurship, IPOs and sustainable

business generation.

”Our decision to locate in Medicon Valley was very

signifi cantly infl uenced by the quality of the work-

force in the region – it is exceptionally high and

fl exible.”Paul Coleman

CEO, Vice President for Government Affairs-International

Biogen Idec

Access to Talent

Percentage of population speaking English

Source: Eurobarometer, European Commission, February 2006

Page 18 | Chapter 4 | Access to Talent

”Our success depends on attracting talent. With a

location in Medicon Valley, we have access to a fi rst-

class pool of scientists and professionals.”

Claus BræstrupPresident and Chief

Executive Offi cerLundbeck (Valby, Denmark)

University of Copenhagen has strengthened its

life science position even further after the mer-

ger in 2007 with the Royal Veterinary and Agri-

cultural University and The Danish University of

Pharmaceutical Sciences. This resulted in adding

the new faculties of Life Sciences and of Pharma-

ceutical Sciences, respectively. More than 1,200

life science PhD students are enrolled at Uni-

versity of Copenhagen.

Lund University educates life science students

at the faculties of medicine, natural sciences,

and technology (Lund University of Technology).

These faculties offer many educational program-

mes, including biochemistry, biophysics, biotech-

nology, biomedicine, medicine and nursing, and

also include the two university hospitals in Malmö

and Lund. About 1,400 life science PhD students

are enrolled at Lund University together with

approx. 900 life science researchers. The under-

graduate and postgraduate programmes, to-

gether with the extensive international student

exchange programmes, secure a steady fl ow of

new and highly qualifi ed researchers both for the

private companies and the universities.

THE ØRESUND UNIVERSITY

The 12 universities in Medicon Valley are further-

more united in the Øresund University alliance.

This alliance increases co-operation between the

universities within education and research. The

alliance also enhances collaboration with busi-

ness and industry in the region as well as with

the public authorities. In this way the best ele-

ments of the two countries’ university systems

can stimulate and spur each other towards be-

coming even better universities.

HIGH MOBILITY

Workforce mobility between the Danish and

Swedish parts of Medicon Valley is high – this is

mostly thanks to the Øresund Bridge that con-

nects the two countries. Nearly 20,000 commu-

ters a day cross the border. A major advantage

of this integrated labour market is that compa-

nies can draw on the strengths of both Swedish

and Danish talents. As a result, more and more

companies are choosing to set up their Scandi-

navian head office or service centre in the

region ensuring instant access to two Scandi-

navian markets and languages. Between 2002

and 2007, 70 headquarters have been placed in

the region, most of them in Copenhagen.

LANGUAGE SKILLS

There are very few language barriers in Medicon

Valley. Almost 90% of the population in Denmark

and Sweden speak English, and many people also

speak German, Spanish or French. According to

the IMD World Competitiveness Yearbook 2007,

the two countries are in the top ten with regards

to language skills. The Danish and Swedish

languages are closely related and readily under-

stood on either side of the border.

ACADEMIC RESOURCES

Within Scandinavia there is a very strong em-

phasis on education. Public spending on education,

as a percentage of GDP, is among the highest

in the world (IMD, World Competitiveness Year-

book, 2007). Subsequently, a continuous supply

of qualifi ed young people is ensured by the regi-

on’s 12 universities of which 5 offer life science

educations.

The two main contributors to life science edu-

cations in Medicon Valley are the University of

Copenhagen, founded in 1470, and Lund Univer-

sity, founded in 1666. These two institutions

account for more than 90% of the life science

related students in Scandinavia. These two uni-

versities are also the two largest in Scandinavia

in numbers of students and researchers.

Percentage of population speaking English

Source: Eurobarometer, European Commission, February 2006

Page 19 | Chapter 4 | Access to Talent

Medicon Valley Universities

• 150,000 students attend the Medicon

Valley universities

• 45,000 students are engaged in life

science related educations

• 2,600 life science PhD students

are enrolled at the universities of

Copenhagen and Lund

• 3,500 scientists are engaged in the

public life science research

��

HB-Medical produces, packs, repacks and fills up for pharmaceutical and biotech companies.

HB-Medical packs and distributes for clinical trials

HB-Medical offers pharmaceutical consulting services

HB-Medical has been approved under section 39 by the Danish Medicines Agency and is authorized by the Danish Veterinary and Food Administration

• Production/packing/repacking• Storage and distribution of study medicine• Storage room with refrigerating facilities• GDP / GMP• Consulting business

Capio Diagnostik a.s.Nygaardsvej 32 DK-2100 Copenhagen O Denmark

www.capiodiagnostik.com

Tel. +45 3374 3000 Fax +45 3374 3030

E-mail: [email protected]

GLP-certified and FDA compliant Laboratory

• Method transfer & method development

• Method validation

• Esoteric tests

• ELISA, RIA, Molecular Biology

��

75ye

ars

for h

ealth

Access to Capital

Page 23 | Chapter 5 | Access to Capital

Venture capital, stock issues and license agree-

ments are all well-known possibilities for fi nan-

cing research company development in Medicon

Valley – given it is a region where companies

historically have succeeded in attracting very

large amounts of capital. The track record for

Medicon Valley is extensive and includes the suc-

cess story of the biotech company Genmab,

which had the largest European private offe-

ring in 2000 and the largest deal worldwide be-

tween biotech and big pharma in 2006.

The high levels of investor attraction to Medicon

Valley companies can mainly be explained by

the fact that the regions well-driven biotech

companies provide a stimulating fl ow of news

based on their sound portfolio of new products.

The intelligent and very active local capital mar-

ket also seems to be of vital importance for the

major international investors in Medicon Valley.

LOCAL INVESTORS

Since the 1990s, the venture capital commu-

nity of Medicon Valley has developed rapidly.

Among the prominent local investors are Novo

A/S, BankInvest, Scandinavian Life Science Ven-

ture and Nordic Biotech. They are all dedicated

biotech investors and in 2007, they had a total

of EUR 1 billion funds under management and

have made more than 120 biotech/life science

investments in their portfolio – local as well as

international.

One of the most important initiatives on the

local investor scene is Sunstone Capital. Sun-

stone Capital was founded in 2007 with more

than EUR 300 million in funds under management.

With a dedicated team of experienced invest-

ment managers, Sunstone Capital focuses on

both developed and developing privately-owned

biotech companies, as well as start-up companies.

Novo Nordisk Foundation has a pre-seed fund

to provide fi nancial, managerial and strategic

support to early stage life science projects.

The funding is given as grants with no claims for

payback or ownership of projects. However, the

pre-seed capital market is managed primarily

by the incubators and innovation environments,

which in most cases are located in connection

to science parks and/or universities.

Novo Nordisk Foundation also manages a seed

fund to support more advanced projects and

initiatives not yet at a stage to be supported

by Novo A/S’s existing venture activities or by

other international investors. The seed fund

operates on commercial terms, i.e. support is

given to projects and companies in exchange

for ownership or other rights relating to the

companies/projects.

”As a both local and international player we have observed a very impressive de-velopment in the local biotech companies – product pipelines have been strengthened, more seasoned and international manage-ment engaged and several companies have taken the transition from private to public.”Søren CarlsenManaging PartnerNovo A/S (Bagsværd, Denmark)

A Venture Capital Adventure

In 2006, the biotech SMEs in Medicon Valley

out-performed their European counter-

parts in attracting venture capital. A total

of EUR 710 million was invested in the region

(Nature Biotechnology, Dec. 2006 and Medi-

con Valley Alliance, 2007).

been among others, 3i, Atlas Ventures, Advent

Venture Partners and Merlin Bioscience.

Nordic Venture Summit is another major event

where national and international investors every

year spend their time in Copenhagen to look for

new investment candidates. With great oppor-

tunities for making business presentations and

meetings, Nordic Venture Summit usually attracts

several hundred executives from biotech, ITC and

the investor community.

LOOKING AHEAD

Companies in Medicon Valley have continued to

be highly attractive for the national and inter-

national investors and have continued to pros-

per. The business environment is characte-

rised by a number of factors which have been

and will remain crucial for development – these

include: great R&D news fl ow; a workforce that

is among the most talented globally; and exit

opportunities which seem to rise even higher as

the biotech companies now market their produ-

cts successfully. Based on such assumptions,

the future looks bright for those engaged in life

science activities in Medicon Valley.

International Investors in Medicon Valley

International investors which have invested

in Medicon Valley biotech companies include

among others, Atlas Ventures (US/UK), Index

Ventures (CH), Global Life Science Ventures

(D/CH), AltaPartners (US), Forbion Capital

Partners(NL), Essex Woodlands Health Ven-

tures (US) and NBGI Venture (UK).

”Given the strong science, industrial base and success

stories, we believe there could be many potentially interes-

ting investment opportunities

in Medicon Valley.”Patrick Lee

General Partner Advent Venture Partners (UK)

Guide to Medicon Valley Investors

The numerous pre-seed, seed and venture

capital investors in Medicon Valley are shown

in the Medicon Valley Financing Guide. The

publication provides information on how and

where to attract venture capital, inclu-

ding profi les and contact information on

75 national and international investors. Get

more information at www.mva.org.

Page 24 | Chapter 5 | Access to Capital

INTERNATIONAL INVESTORS

PRESENT IN MEDICON VALLEY

Medicon Valley has experienced remarkable atten-

tion from international investors. In 2006, every

second investor involved in fi nancing rounds in

Medicon Valley biotech companies was from the

international scene. The international investor

community regards Medicon Valley companies

as a very appealing prospect, due to their world

class research, effi ciency and high performan-

ce and also the fact that they are placed in one

of the leading life science clusters in the world

in terms of converting science into patents and

patents into products (Ernst & Young, Beyond

Borders, 2006). Moreover, the presence of phar-

maceutical companies in Medicon Valley for almost

a century means that substantial know-how on

drug development has been transferred into the

local biotech companies. This local know-how

has been one of the key drivers for the late

stage companies’ success in attracting major

international investments.

The international investor awareness of Medi-

con Valley companies seems to be even higher

following the international exposure of the break-

through deals of Genmab and Bavarian Nordic.

As mentioned earlier, these two deals account

for a potential USD 2.1 billion (Genmab, 2006)

and USD 1.6 billion (Bavarian Nordic, 2007).

Another success story is BioInvent, who in 2007

entered in collaboration with Genentech for a

potential 190 million USD.

Several biotech and medtech companies have

made successful IPOs. During 2006-07, Curalogic

Exiqon and LifeCycle Pharma consolidated their

businesses by entering the Nordic Stock Ex-

change OMX, and CellaVision, Genovis and Hansa

Medical were publicly listed on the OMX First North.

INTERNATIONAL EXPOSURE

OF LOCAL COMPANIES

Various activities raise the exposure of Medi-

con Valley companies towards international in-

vestors. The Strictly Financing Award is the

annual investor fl agship event in Medicon Valley,

where a number of its biotech and medtech

companies are nominated to give business pre-

sentations towards a panel of large internatio-

nal investors. The panel decides which company

earns the title as the Best Biotech Company

in Medicon Valley. Participating investors have

The high numbers of life science companies in

Medicon Valley has led to the development of an

effi cient support structure holding a broad range

of life science related service companies and

network organisations. Patent and business at-

torneys, management consultants, investors,

and recruitment companies often have estab-

lishments close to incubators and science parks.

The large fl ow of products in development in

Medicon Valley requires, among other things,

preclinical and clinical research support. Medicon

Valley’s many CROs, CMOs and 11 university hos-

pitals help provide this.

TECH TRANSFER ORGANISATIONS

AND INCUBATORS

The universities and main hospitals have Tech-

nology Transfer Organisations (TTOs), which can

assist with issues around IPRs, out-licensing

or company start-up. Since 2000, Danish uni-

versities have taken ownership of inventions

performed by their researchers, while Swedish

university employees still rely on the “Teacher’s

Exempt”, meaning they are private owners of

their inventions and can choose whether to use

the services of a TTO.

As from 2007, all the technology transfer units

at the Copenhagen-area hospitals have mer-

ged into one TTO placed at the State University

Hospital. At all major hospitals, so-called inno-

vation ambassadors secure an easy access to

the relevant expertise and subsequent coordi-

nation of all the commercialisation resources in

the system in order to secure a steady fl ow of

new business opportunities. The merger of the

three life science universities in Copenhagen

into one has also meant a combined and more

effi cient university technology transfer unit.

In Skåne, the commercialisation of research is

facilitated through a number of collaborating

organisations, including Lund University Inno-

vation System (LUIS) and Innovationsbron Syd,

which is active via Forskarpatent i Syd, Teknopol

and several incubators. It is also worth mentio-

ning Lund Bioscience, which is a new life science

investment fund started in 2007.

Lund Bioincubator at BMC, which welcomed the

fi rst companies in 2007, offers advanced la-

boratory premises for carrying out proof-of-

concept studies. The bioincubator supports

selected companies for up to 3 years through

subsidized rent of the facilities in addition to

offering business development services, educa-

tion and access to various networks. In 2009,

Copenhagen Bio Science Park (COBIS) will open

in central Copenhagen creating a unique envi-

ronment for fostering new biotech companies

at international level. COBIS will offer state-

of-the-art facilities as well as a wide range of

business development services.

Support Structure

”The excellent science parks and incubators in Medicon Valley provide high quality growth conditions with access

to professional networks, labs and services.”Charlotte Ahlgren

Managing DirectorMedeon Science Park (Malmö, Sweden)

Page 26 | Chapter 6 | Support Structure

FULL SERVICE SCIENCE

Medicon Valley hosts six science parks with a

signifi cant focus on life science and another six

incubators. Both science parks and incubators

are situated in close proximity to universities

and other hi-tech environments. They are an

important element in stimulating co-operation

between universities, industry and venture ca-

pital providers. The science parks in Medicon

Valley offer a wide range of services, including

administrative and fi nancial services from seed

capital to venture capital, legal advice and coun-

selling in relation to establishment, networking,

patent applications, marketing, licenses, capital

input etc.

HIGH QUALITY AND COST

EFFECTIVE CLINICAL TRIALS

Denmark and Sweden have long been known for

the high quality of clinical trials, with Good Clini-

cal Practice implemented very early. The willing-

ness of both sets of populations to participate

in clinical trials is high, and this is due to the

focus on safety for test persons, the physicians’

obligation to give thorough information and the

high trust in companies conducting the tests.

This means that the number of drop outs is

limited. Patient organisations are positive to

clinical trials, and may prove helpful in contac-

ting potential study participants or distributing

information about studies.

Compared to the US, the cost of conducting

clinical trials is substantially lower in both Den-

mark and Sweden. One of the reasons for this is

that volunteers who participate in the trials are

remunerated with only a token payment.

Science Parks

• Scion-DTU

(www.sciondtu.dk)

• Symbion Science Park

(www.symbion.dk)

• CAT Science Park

(www.catscience.dk)

• Ideon Science Park

(www.ideon.se)

• Medeon Science Park

(www.medeon.se)

• Krinova Science Park

(www.krinova.se)

Incubators

• DTU Innovation

(www.dtu-innovation.dk)

• Cat-Symbion Innovation

(www.catsymbioninnovation.dk)

• Teknologisk Innovation

(www.tekinno.dk)

• Ideon Innovation

(www.ideoninnovation.se)

• Medeon Incubator

(www.medeon.se)

• Lund BioIncubator

(www.lundbioinkubator.se)

”The biomedical infrastructure here is completely solid – with excel-lent universities, hospitals and clinical research support. We have a very powerful platform for rapid drug development.”Lisa DrakemanPresident and Chief Executive Offi cerGenmab (Copenhagen, Denmark)


ceutical R&D based manufacturers and the fl ora

of small and medium sized biotech companies.

Already, Medicon Valley is at the forefront of

developing personalised medicine – and this is

set to grow.

REGISTRATION AND CERTIFICATION

OF MEDICINES AND MEDICAL DEVICES

The regulatory authorities have a very good

reputation and are in the top three as reporters

in EU for mutual recognition throughout Europe.

Non-European companies also frequently use

the Scandinavian countries for performing cli-

nical trials and registrations. For medical de-

vices, there are Notifi ed Bodies, which can be

contracted to perform certifi cation for type II

and III devices.

CONTRACT RESEARCH AND

MANUFACTURING ORGANISATIONS

OF A HIGH STANDARD

Both domestic and international contract re-

search organisations (CROs) are represented

in Medicon Valley, including the headquarters

of Sweden’s and Denmark’s largest CROs. The

CROs are well established and renowned for their

high standards of quality. They offer a variety

of services and many are capable of conducting

complete preclinical and clinical projects from

start to fi nish, naturally carried out in accordance

with guidelines for both Good Laboratory Prac-

tice (cGLP) and Good Clinical Practice (cGCP).

A number of contract manufacturing organi-

sations (CMOs) are also present, offering effi -

cient manufacturing in accordance with Good

Manufacturing Practice (cGMP) standards.

A COMPREHENSIVE POPULATION

REGISTRATION SYSTEM

The two countries’ social health care systems

provide further benefi ts for clinical research. All

Danish and Swedish citizens have free and equal

access to healthcare, and medical and genetic

data are tracked from birth to death through the

central population register. This ensures that

all population segments are represented in samp-

ling. The two countries’ databases are also among

the most comprehensive, sophisticated and well-

maintained in the world.

This applies to the Danish Cancer Register, which

has existed since 1943 and the Swedish Cancer

Register which dates back to 1957. The regi-

sters contain data on the occurrence of cancer

and other diseases subjected to notifi cation.

The permission to use these registers and the

notifi cation of diseases is a great advantage

when doing clinical trials, as it makes it possible

to track patients over time and to gain a deeper

insight into their medical history.

Another advantage is the biobanks which enable

important research to be carried out – infor-

mation from biobanks is coupled to national

registries. This is unique for the Nordic coun-

tries.

AN EXCEPTIONAL PLACE TO

DEVELOP PERSONALISED MEDICINE

The concept of personalised medicine – being the

understanding of the molecular basis of health

and disease, and the development of highly tar-

geted and individualised diagnostics and thera-

peutic regimens – will become a reality within the

next decade. This emergence of targeted the-

rapies will generate unique opportunities for all

stakeholders across the entire life science value

chain.

Medicon Valley has a signifi cant advantage in its

effort to make this exciting new concept a rea-

lity. This is due to the region’s long experience

in private public partnerships, the unmatched

infrastructure in combination with the presence

of several diagnostic companies, major pharma-


Drug and Device Development Guide

The Drug and Device Development Guide

gives information about the CROs and

regional hospital departments that are

involved in clinical trials. Order the guide at

www.mva.org.

Number of NCE rapporteurships in the centralized procedure in Europe 1995-2004

Medicinal products for human use. Source: NDA Regulatory Science Ltd UK, 2007.


Due to its geographical location and connec-

tivity, Medicon Valley is the natural key point of

entry into Scandinavia. It serves as the Scandi-

navian hub and traffi c linkage point between the

region and the Baltic countries. Copenhagen

Airport offers the largest number of direct

intercontinental, European, Scandinavian and

Baltic fl ight connections in Scandinavia. By using

the Metro, you can arrive in the centre of Copen-

hagen a mere 15 minutes later and with the Øre-

A Location in Medicon Valley Ensures:

• Close proximity to a large number of delivery points

• Effi cient modes of transportation that allow distributors to plan logistics fl ows in an effi cient

manner

• New terminals and intermodal transportsystems in place linking air, sea, road and rail transport

• Major full-service logistics providers such as FedEx and DHL, which have placed their Nordic

operations in Copenhagen, providing excellent services and outsourcing opportunities

• Access to a highly effi cient public transportation system

Infrastructuresund train you reach Malmö in about the same

time span.

MEDICON VALLEY – A NEW SCANDINAVIAN BASE

The Øresund Bridge between Copenhagen and

Malmö has expanded the highway network and

linked Denmark and Sweden more effectively in

and around Medicon Valley. The travel distance

between the two cities has been reduced to just

30 minutes.

Page 32 | Chapter 7 | Infrastructure

Furthermore, Øresund trains crossing the bridge

every 20 minutes effi ciently link the cities and

towns of Denmark and Sweden. At the northern

end of Øresund, ferries link Helsingborg and

Helsingør every 15 minutes.

The Copenhagen-Malmö Port, which has a total

cargo turnover of 15.2 million tons per annum,

has scheduled routes to many Nordic and Baltic

Sea harbours – often with daily services.

Copenhagen Airport is the largest cargo airport

in northern Europe, handling over 350,000 tons

of cargo every year, and with direct fl ights to

more than thirty cargo destinations.

Another important airport is Malmö Airport,

which is located just outside the city with a

short trip of only 15 minutes to Lund and 60

minutes to Copenhagen.

Page 33 | Chapter 7 | Infrastructure

The Øresund region is an area that refl ects the

modern age with eastern Denmark and southern

Sweden complementing one another in a commu-

nity without frontiers.

ADVANCED LIFESTYLE

Medicon Valley offers an advanced lifestyle that

is highly attractive for creative professionals

and companies wanting to lead the marketplace

through innovation. The work-life balance, de-

signed for the benefi t of society, technological

superiority and a unique green environment are

all aspects of the lifestyle.

Inhabitants in Medicon Valley are among the world’s

most affl uent in both monetary and quality of

life terms. Denmark and Sweden are in the top

10 of the world’s best countries to live in, accor-

ding to The Economist. Copenhagen has recei-

ved very good rankings in international surveys

focusing on quality of life as well as happiness.

A PERFECT BALANCE

In Medicon Valley, combining work and family life

is a different experience. It is a pleasantly posi-

tive surprise for many – and highly appealing to

professionals. In Medicon Valley, you are able to

have a career that is on track as well as a ful-

fi lling family life. Workplaces prioritise fl exible

working hours and cater for the family life of

their employees without compromising produc-

tivity. Free schools and health services, easy

access to childcare and a safe and a healthy

environment are just some of the benefi ts you

can enjoy. Not surprisingly, we hear business

professionals refer to the region as “the busi-

ness world’s best kept secret”.

VIBRANT CULTURE

On top of all this, Medicon Valley also offers

places such as Copenhagen and Malmö – cities

that are culturally sophisticated, vibrant, clean

and safe. Both cities are designed to accommo-

date bicyclists and pedestrians – one reason the

region’s motor traffi c congestion is relatively low.

CLOSE TO NATURE

Medicon Valley is a diverse and fascinating re-

gion from many perspectives. The region as a

whole is bordered by wonderful sandy beaches

and you are never far from green forests and the

countryside. Equally, spending time in Copenhagen

and Malmö will also give you a taste of modern

urban life, which is greener and less polluted.

The waterfront on both sides of Øresund is so

clean that it is possible to take a swim in the

open-air baths or the inner harbour beaches.

Moreover, the coast of Øresund offers un-

limited access to several beaches and marinas.

You can easily go by train, car or bike to beaches

and forests – all within only a short distance !

Quality of Life

Page 34 | Chapter 8 | Quality of Life

Why Medicon Valley ?

• The region has high job quality and happy

employees: Scandinavian colleagues are

teamplayers, fl exible to work with, innova-

tive and productive. Scandinavian work-

places also show a great deal of respect

for family life.

• The quality of living is high in the region:

A positive balance between family and

work life, with no need to spend hours in

traffi c jams – public services are fast and

effi cient.

• The region is a safe and sound place for

families offering an ideal environment to

raise children – personal safety is high

and pollution is low.

• There is high satisfaction with recreatio-

nal activities – including entertainment,

restaurants, music, arts, theatres, and

sports facilities.

”Many people are attracted to the region because of the large and

varied labour market and also because it offers a very comfortable and

enjoyable life style.”Cristina Glad

Executive Vice PresidentBioInvent (Lund, Sweden)

Page 35 | Chapter 8 | Quality of Life

Medicon Valley Alliance (www.mva.org) is the cluster organisation for

Medicon Valley. We facilitate network and knowledge sharing activities

between private and public players and manage cluster development

projects. We have a strong international network and are involved in

cluster-to-cluster collaborations with bioregions worldwide. Our 270 mem-

bers are made up of life science companies, universities, hospitals and

service providers in Medicon Valley.

Copenhagen Capacity (www.copcap.com) is the offi cial investment pro-

motion agency for Greater Copenhagen, the Capital Region of Denmark

and part of the Øresund Region. Copenhagen Capacity is publicly funded

and provides free assistance to foreign companies interested in estab-

lishing activities or contacts in Medicon Valley, especially in the Danish

part of Medicon Valley.

Region Skåne, Department of Economic Development & Innovation

(www.skane.com/invest) is the official organisation responsible for

investment promotion for Skåne, Sweden’s southernmost region and

part of the Øresund Region. Region Skåne is publicly funded and provides

free assistance to foreign companies interested in establishing activities

or contacts in Medicon Valley, especially in the Swedish part of Medicon

Valley.

Page 39 | Chapter 9 | Point of Entries

Point of Entries

© Copenhagen Capacity | Region Skåne | Kiberg & Gormsen

Get more information !

Please feel free to contact us with your questions about Medicon Valley. We are here to help.

Medicon Valley AllianceDenmark

Arne Jacobsens Allé 15, 2.

DK-2300 Copenhagen S

Tel: +45 35 32 41 50

Fax: +45 35 32 41 59


Web: www.mva.org

Medicon Valley AllianceSweden

Øresundshuset

Box 117

SE-221 00 Lund

Visit: Østra Vallgatan 14, Lund

Tel: +46 46 222 16 80

Fax: +46 46 222 09 84


Web: www.mva.org

Copenhagen Capacity

Gammel Kongevej 1

DK-1610 Copenhagen V

Denmark

Tel: +45 33 22 02 22

Fax: +45 33 22 02 11


Web: www.copcap.com

Region Skåne

Department of Economic

Development & Innovation

Stortorget 9

SE-211 22 Malmö

Sweden

Tel: +46 40 623 9748

Fax: +46 40 623 9753


Web: www.skane.com/invest

Get more information atwww.mediconvalley.com

Date post:	12-Oct-2014
Category:	Documents
Upload:	pramila-s-das
View:	65 times
Download:	8 times

Medicon Valley Cluster

Documents